Q32 Bio is developing bempikibart, an injected antibody for severe alopecia areata (autoimmune hair loss); it is not approved.
Bempikibart blocks IL-7 and TSLP signaling. In the open-label SIGNAL-AA Part B trial in severe or very severe alopecia areata, it cut SALT scores 35.3% at Week 36, with 40% of patients reaching SALT-20. Responses held for 16 weeks off drug in all 12 patients with hair growth. Q32 plans a registration-directed program in the first half of 2027 after FDA discussions this half. Cash plus the July offering funds operations through Phase 3 topline.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FDA discussions set the registration path
Does FDA feedback support a registration-directed program in severe or very severe alopecia areata starting in early 2027?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Bempikibart heads to registration-directed alopecia trials in 2027, funded through Phase 3 data
Phase 2a win and fresh $200M gives bempikibart a clear run at registration — but a single-arm, open-label dataset must hold up in a controlled pivotal trial
Positive alopecia areata trial data announced
Bempikibart's mid-2026 Phase 2a readout in severe alopecia areata is the single event that validates or breaks this company's entire investment case
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Skin diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
2 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.